Experimental allergic encephalomyelitis: peculiarities of pain-relieving therapy and place of anti¬con¬vulsants as analgetics.
DOI:
https://doi.org/10.26641/2307-0404.2015.4.56125Ключевые слова:
multiple sclerosis, anticonvulsants, "open field", painАннотация
Multiple sclerosis (MS) is the most common demyelinating disease affecting mainly young people of the working age (16-45 years) and quickly leading to disability. Available data constitute that up to 80% of MS patients suffer from pain at different disease periods. Pain management and the analgesic drug choice in MS patients may be difficult. Anticonvulsant drugs possess an analgesic activity and are widely used in patients presenting painful neuropathic symptoms. Based on that, we aimed to investigate the nociceptive potential changes as well as the research-oriented behavior using the "open field" test in rat. An experimental animal equivalent of multiple sclerosis has been modeled, based on the methylprednisolone (M) administration. Animals were also administered anticonvulsants (carbamazepine, topiramate, sodium volproat, pregabalin and gabapentin). The study showed advantages of gabapentin and pregabalin use in simulated disease treatment. This statement is based on the "open field" test results, where the motor-oriented rats’ behavior was evaluated. Administration of M+gabapentin and M+pregabalin showed positive dynamics of the motor activity: the number of squares crossed increased by 80.86% (p<0.05) and 81.73% (р<0.05) respectively. Maximum recovery of the research activity (peeking in "mink") was registered in animals administered M+pregabalin: the increase rate was 300% (r<0.05) comparing with the 12th day of experiment. It was shown, that 5-days administration of M+gabapentin and M+pregabalin caused muscle tone improvement by 190% (p<0.05) and 200% (p<0.05) respectively, comparing with animals with untreated multiple sclerosis. A significant increase of analgesic activity of M+pregabalin and M+gabapentin combinations used together with methylprednisolone by 4.1 (p<0.05) and 3.6 (p<0.05) times was registered comparing with the initial methylprednisolone background.
Библиографические ссылки
Viktorov OP, Makarenko OV, Mamchur VJ, Dro¬nov SM. [Algorithms of clinical use of antipain drugs (narcotic and non-narcotic analgesics) in acute and chronic syndrome. Guidelines] Kyiv. DETs Ukrainy. 201;56. Ukrainian. 2. Donchenko HV. [Experimental allergic encephalomyelitis: some indicators of energy, protein and lipid metabolism] Nejrokhymyia. 2007; :232-8. Russian. 3. Ethics of a physician and human rights: the regu¬lation of the use of animals in biomedical research. Clinical and Experimental physiology and biochemistry. 2003;2(22):108-9. Ukrainian. 4. Kaluev AV. [Stress, anxiety and behavior. Actual problems of modeling of anxious behavior in animals] Kyev. 1998;95. Russian. 5. Lapach SN, Chubenko AV, Babych PN. [Statis¬tical methods in biomedical research using EXCEL] K.«Moryon». 2001;408. Russian. 6. Mel'nykov AV, Kulykov MA, Novykova MR. [The choice of indicators of behavioral tests to assess the typological features of behavior of rats] Zhurnal vysshej nervnoj deiatel'nosty. 2004;54(5):712–7. Russian. 7. Kozhem'iakin YuM, Khromov OS, Filonen¬ko MA, Sajretdynova HA. [Scientific and practical advice on keeping laboratory animals and work with them] K. 2002;155. Ukrainian. 8. Nef'odov OO, Mamchur VJ, Kharchenko YuV. [Feed¬back on modeling and experimental allergic ence¬phalomyelitis] Visnyk problem biolohii i medytsyny. 2014;2(114):205-8. Ukrainian. 9. Opryshko VI. [Experimental pharmacotherapy of pain in terms of increased convulsive readiness of the brain] Farmakolohiia ta likars'ka toksykolohiia. 2009;4(11):3-9. Ukrainian. 10. Baker D, Hankey DJ. Gene therapy in autoim¬mune, demyelinating disease of the central nervous system. Gene Ther. 2003;10(10):844-53. 11. Brune K, Lanz K. Mode of action peripherical analgesic. Arzneimittel – Forsch. 1984;34(9a):1060-5. 12. Cotte S, von Ahsen N, Kruse N. ABC-transporter gene-polymorphisms are potential pharmacogenetic mar¬kers for mitoxantrone response in multiple sclerosis. Brain. 2009;132(9):2517-30. 13. Jawahar R, Oh U, Yang S. A systematic review of pharmacological pain management in multiple sclerosis. Drugs. 2013;73(15):1711-22. 14. Siniscachi A, Gallelli L, De Sarro G. Drugs treat¬ment of pain in multiple sclerosis. Curr Clin Pharmacol. 2007;2(3):227-33. 15. Ehde DM, Alschuler KN, Osborne TL et al. Utili¬zation and patients perception of the effectiveness of pain treatments in multiple sclerosis: a cross-sectional survey. Disabil Health J. 2015;8:452-6.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2017 Medical Perspectives
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 4.0 Всемирная.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
